BD receives 510(k) clearance for fingerstick blood test sample collection device
The clearance positions BD and partner Babson Diagnostics to support blood collection from community sites such as pharmacies.
Uncategorized
White House sets April target for finalization of FDA rule on lab developed tests
TD Cowen analysts said it is “unclear if and when FDA will finalize the rule as it has faced considerable opposition.”
NiKang Therapeutics Enters into Clinical Trial Collaboration and Supply Agreement to Evaluate NKT2152 in Combination with Standard-of-Care in First-Line Advanced Hepatocellular Carcinoma
NiKang Therapeutics Inc. today announced that it has entered into a clinical trial collaboration and supply agreement with F. Hoffmann-La Roche Ltd. (“Roche”) to evaluate NKT2152, a small molecule that inhibits hypoxia inducible factor 2α (HIF2α), in combination with standard-of-care atezolizumab (Tecentriq®) and bevacizumab (Avastin®) in first-line treatment of unresectable/advanced hepatocellular carcinoma (HCC).
MEDSIR presents promising results at SABCS 2023: ATRACTIB and DEBBRAH trials hold potential to improve the lives of advanced breast cancer patients
MEDSIR, a global leader in oncology research, today presented significant breakthroughs in the fight against aggressive breast cancer at the 46th San Antonio Breast Cancer Symposium (SABCS) that have the potential to transform the lives of breast cancer patients.
AMGEN HIGHLIGHTS HEMATOLOGY PORTFOLIO AT ASH 2023
Amgen (NASDAQ:AMGN) today announced the presentation of new data from its blood cancer portfolio and pipeline at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place from Dec. 9-12 in San Diego.
Latest Novartis Kisqali® NATALEE analysis reinforces 25% reduction in risk of recurrence across broad population of patients with early breast cancer; supports regulatory submissions – December 8, 2023
Novartis today announced results from an updated invasive disease-free survival (iDFS) analysis of the pivotal Phase III NATALEE trial, with a median follow-up of 33.3 months and following Kisqali® (ribociclib) treatment completion by 78.3% of patients.
Alveolus Bio Enters Into Strategic Collaboration with BiomEdit
Alveolus Bio today announced a strategic scientific collaboration with BiomEdit, an emerging animal health biotechnology company leveraging microbiome science and synthetic biology to develop novel products to prevent and treat disease in animals.
Intensity Therapeutics Presents Positive INT230-6 Data in Patients with Early-Stage Breast Cancer in a Podium Poster Spotlight Discussion at the 2023 SABCS
Intensity Therapeutics, Inc. today announced that safety, tolerability, efficacy and immune activation data from the company’s Phase 2 INVINCIBLE trial of INT230-6 in patients with early-stage breast cancer without chemotherapy was presented at a Podium Poster Spotlight discussion session today during the 2023 San Antonio Breast Cancer Symposium (SABCS). Information on the presentation is below.
Merck’s Keytruda Flops in Late-Stage Endometrial Carcinoma Study
For the second time in as many days, Merck has reported a Phase III failure for its blockbuster PD-1 inhibitor Keytruda, this time as a first-line treatment with Eisai’s Lenvima for cancer in the uterus lining.
BMS Builds Case for Opdivo, Yervoy Combo in First-Line Colorectal Cancer
Results from a Phase III trial showed the combination improves progression-free survival compared to chemotherapy when used as a first-line treatment in metastatic colorectal cancer.